My research is centered on improving the quality of life for individuals living with serious and life-limiting illnesses. A core area of focus is the comparative effectiveness of medical cannabis versus traditional prescription pharmacotherapies in managing pain and other burdensome symptoms such as nausea, anxiety, and appetite loss. This includes evaluating not only clinical outcomes, but also the safety, accessibility, and patient-centered implications of integrating cannabis-based interventions into serious illness care.
In parallel, my work explores how interdisciplinary, team-based care models can be optimized to provide holistic support to patients and their families. I am particularly interested in developing metrics that meaningfully capture the impact of collaborative care on patient outcomes, caregiver burden, and overall healthcare utilization.
These intersecting areas of inquiry have directly shaped my efforts in academic leadership, including the development and ongoing direction of the Master of Science in Medical Cannabis Science & Business program. This program reflects my commitment to advancing evidence-based education, research, and policy related to emerging therapies in supportive oncology and palliative care.